Olinciguat - Ironwood Pharmaceuticals

Drug Profile

Olinciguat - Ironwood Pharmaceuticals

Alternative Names: IW 1701

Latest Information Update: 08 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ironwood Pharmaceuticals
  • Class Antifibrotics; Cardiovascular therapies; Oxazoles; Pyrazoles; Pyrimidines
  • Mechanism of Action Soluble guanylyl cyclase agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastrointestinal disorders; Sickle cell anaemia
  • Phase I Cardiovascular disorders; Fibrosis

Most Recent Events

  • 07 Jun 2018 Olinciguat - Ironwood Pharmaceuticals receives Orphan Drug status for Sickle cell anaemia in USA
  • 04 Jun 2018 Chemical structure information added
  • 03 Jan 2018 Pharmacodynamics data from a preclinical trial in Cardiovascular disorders presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top